Asthma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older and are receiving specialist care for either severe asthma or chronic spontaneous urticaria (a long-term skin condition causing hives).
- You have been treated with the medication omalizumab (the original/reference version) for at least 6 months for one of the conditions listed above.
- Your condition has been stable for at least 3 months, meaning your doctor considers it controlled or in remission — for asthma this is based on specific breathing test results and low use of steroid tablets, and for urticaria this is based on a symptom score (confirm with trial site).
- Your specialist doctor has already decided, as part of your normal care, to switch you to a medication called OMLYCLO® (a biosimilar version of omalizumab made by Celltrion).
- You are able to start the new treatment within 60 days of joining the study.
- You have an email address and a mobile phone number.
- You are able to understand and fill in questionnaires written in French.
- You agree to take part in the study.
- You are covered by the French Social Security system.
Who may not be able to join:
- You are under legal guardianship, trusteeship, or are otherwise not free to make your own decisions.
- You are pregnant or could become pregnant and are planning to do so during the treatment period.
- You are already taking part in another clinical trial or study that does not allow you to join additional studies at the same time.
- You have a medical reason why you cannot take the study medication (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +33 1 71 25 27 00
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Maintenance of disease control and/or remission 12 months after initiation of biosimilar treatment.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.